The effect of the combination of estetrol and drosperinone on the quality of life and sexual function of women

Karakhalis L.Yu., Tikhaya V.R., Chervonnaya I.Yu., Efremenko Yu.S., Khalafyan А.А.

1) Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia; 2) Regional Clinical Hospital No. 2, Ministry of Health of the Krasnodar Region, Krasnodar, Russia; 3) Yekaterininskaya Clinic LLC, Krasnodar, Russia; 4) Kuban State University, Ministry of Science and Higher Education of the Russian Federation, Krasnodar, Russia

Objective: To study the effect of an oral contraceptive containing estetrol 15mg and drosperinone 3mg (Esteretta) on the sexual function and the quality of life in women of reproductive age.
Materials and methods: A total of 40 women were examined whose average age was 29.5±4.2 years; they were administered a combined oral contraceptive (COC) containing estetrol 15 mg and drospirenone 3 mg. Before taking the medication and six months after it, a survey was conducted on the issues of the Female Sexual Function Index (FSFI) and on the SF-36 (Short Form Medical Outcomes Study) questionnaire about the quality of life.
Results: There was an improvement in the following parameters of quality of life in six months: PF (physical functioning) increased by 14.45 scores; role physical (RP) increased by 34.5 scores; perception of bodily pain (BP) decreased; initially low score of general health (GH) increased from 52 scores to 77.5 scores; vitality (VT) increased by 11 scores; social functioning (SF) increased by 6 scores; role emotional (RE) increased by 38 scores; low parameters of mental health which were associated with the presence of depression, anxiety, and mental ill-being increased by 18 scores. According to the results of FSFI, the number of women without difficulty in lubrication increased significantly, the number of women who had orgasm increased, and number of patients with discomfort and pain during sexual intercourse decreased.
Conclusion: The combined oral contraceptive containing estetrol 15 mg and drospirenone 3 mg significantly improved the quality of life and affected the clinical manifestations of sexual disorders.

Authors’ contributions: Karakhalis L.Yu. – development of the concept, design and methodology, analysis and interpretation of the obtained data, preparation and editing of the text, approval of the final version of the article; Tikhaya V.R., Chervonnaya I.Yu. – conducting the study (analysis and interpretation of the obtained data); Efremenko Yu.S. – conducting the study (analysis and interpretation of the obtained data), preparing the text, editing; Khalafyan A.A. – statistical analysis, editing the article.
Conflicts of interest: Authors declare lack of the possible conflicts of interests.
Funding: The study was conducted without sponsorship.
Ethical Approval: The study was approved by the Ethical Review Board of the Kuban State Medical University, Ministry of Health of Russia, Krasnodar.
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Karakhalis L.Yu., Tikhaya V.R., Chervonnaya I.Yu., Efremenko Yu.S., Khalafyan А.А. The effect of the combination of estetrol and drosperinone on the quality of life and sexual function of women.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (2): 118-122 (in Russian)
https://dx.doi.org/10.18565/aig.2024.1

Keywords

combined oral contraceptives
sexual function
quality of life

References

  1. United Nations DoEaSA, Population Division. Contraceptive use by method 2019: data booklet. (ST/ESA/SERA/435). 2019.
  2. Foidart J.M., Gemzell-Danielsson K., Kubba A., Douxfils J., Creinin M.D., Gaspard U. The benefits of esterol addition to drosperinone for contraception. AJOG Glob. Rep. 2023; 3(4): 100266. https://dx.doi.org/10.1016/j.xagr.2023.100266.
  3. Hagen A.A., Barr M., Diczfalusy E. Metabolism of 17-beta-oestradiol-4-14-C in early infancy Acta Endocrinol. (Copenh). 1965; 49: 207-20.
  4. Abot А., Fontaine C., Buscato M., Solinhac R., Flouriot G., Fabre A. et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation. EMBO Mol. Med. 2014; 6(10): 1328-46. https://dx.doi.org/10.15252/emmm.201404112.
  5. Arnal F., Lenfant F., Metivier R., Flouriot G., Henrion D., Adlanmerini M. et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol. Rev. 2017; 97(3): 1045-87. https://dx.doi.org/10.1152/physrev.00024.2016.
  6. Foidart J.M., Gaspard U., Pequeux C., Jost M., Gordenne V., Tskitishvili E. et al. Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST). In: Daz Brinton R., Genazzani A.R., Simoncini T., Stevenson J.C., eds. Sex steroids' effects on brain, heart and vessels. vol.6: Frontiers in gynecological endocrinology. Basel Switzerland: Springer International Publishing; 2019.
  7. Guivarc'h E., Buscato M., Guihot A.L., Favre J., Vessières E., Grimaud L. et al. Predominant role of nuclear versus membrane estrogen receptor alpha in arterial protection: implications for estrogen receptor alpha modulation in cardiovascular prevention/safety. J. Am. Heart Assoc. 2018; 7(13): e008950. https://dx.doi.org/10.1161/JAHA.118.008950.
  8. Сухих Г.Т., Прилепская В.Н., Аганезова Н.В., Андреева Е.Н., Баранов И.И., Долгушина Н.В., Зароченцева Н.В., Карахалис Л.Ю. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5 издание, 2015 ». М.; 2023. [Sukhikh G.T., Prilepskaya V.N., Aganezova N.V., Andreeva E.N., Baranov I.I., Dolgushina N.V., Zarochentseva N.V., Karakhalis L.Yu. National medical criteria for the acceptability of contraception methods. Adapted document "WHO Medical Eligibility Criteria for the Use of Contraceptive Methods, 5th Edition, 2015." M.; 2023. (in Russian)].
  9. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey. Manual and interpretation guide. The Health Institute, New England Medical Center. Boston, Mass.1993.
  10. Карахалис Л.Ю., Захарова Е.С., Халафян А.А., Козыр Л.Н., Пенжоян Г.А. Гиперандрогенная дермопатия в практике акушера-гинеко­лога. Вопросы гинекологии, акушерства и перинатологии. 2022; 21(6): 131-8. [Karakhalis L.Yu., Zakharova E.S., Khalafyan A.A., Kozyr L.N., Penzhoyan G.A. Hyperandrogenic dermopathy in the practice of obstetrician-gynecologists. Gynecology, Obstetrics and Perinatology. 2022; 21(6): 131-8. (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2022-6-131-138.
  11. Аполихина И.А., Прилепская В.Н., Горбунова Е.А., Межевитинова Е.А., Бычкова А.Е. Эстетрол – новая ступень комбинированной гормональной контрацепции. Акушерство и гинекология. 2023; 3: 134-40. [Apolikhina I.A., Prilepskaya V.N., Gorbunova E.A., Mezhevitinova E.A., Bychkova A.E. Estetrol – a new stage of combined hormonal contraception. Obstetrics and Gynecology. 2023; (3): 134-40. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.72.
  12. Акиньшина С.В., Колода Ю.А. Особенности влияния нового контрацептива с эстетролом на профиль тромботической безопасности гормональной контрацепции. Акушерство и гинекология. 2022; 10: 159-68. [Akinshina S.V., Koloda Yu.A. The effect of a new contraceptive with estetrol on the thrombotic safety profile of hormonal contraception. Obstetrics and Gynecology. 2022; (10): 159-68. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.10.159-168.

Received 09.01.2024

Accepted 30.01.2024

About the Authors

Lyudmila Yu. Karakhalis, Dr. Med. Sci., Professor, Professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Continuing Education and Professional Retraining of Specialists, Kuban State Medical University, Ministry of Health of the Russian Federation, 350063, Russia, Krasnodar, Mitrofana Sedina str., 4;
obstetrician-gynecologist, Regional Clinical Hospital #2», Ministry of Health of the Krasnodar Region, +7(988)244-40-44, lomela@mail.ru, https://orcid.org/0000-0003-1040-6736
Victoria R. Tikhaya, obstetrician-gynecologist, Regional Clinical Hospital #2», Ministry of Health of the Krasnodar Region, https://orcid.org/0000-0001-7174-6529
Irina Yu. Chervonnaya, PhD, obstetrics gynecologist, Yekaterininskaya Clinic, Krasnodar, https://orcid.org/0009-0000-8695-5219
Yuliya S. Efremenko, Clinical Resident, Department of Obstetrics, Gynecology and Perinatology, Faculty of Continuing Education and Professional Retraining of Specialists, Kuban State Medical University, Ministry of Health of the Russian Federation, 350063, Russia, Krasnodar, Mitrofana Sedina str., 4, yuliya2397@mail.ru,
https://orcid.org/0009-0008-4745-1411
Aleksan A. Khalafyan, Dr. Tech. Sci., Professor at the Department of Data Analysis and Artificial Intelligence FPM, Kuban State University, Ministry of Science and Higher Education of the Russian Federation, 350040, Russia, Krasnodar, Stavropolskaya str., 149, statlab@kubsu.ru, https://orcid.org/0000-0003-2324-3649
Corresponding author: Lyudmila Yu. Karakhalis, lomela@mail.ru

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.